The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome
Open accessAbstract
Purpose: Classical Hodgkin lymphomas (cHLs) include small numbers of malignant Reed-Sternberg cells within an extensive but ineffective inflammatory/immune cell infiltrate. In cHL, chromosome 9p24.1/PD-L1/PD-L2 alterations increase the abundance of the PD-1 ligands, PD-L1 and PD-L2, and their further induction through Janus kinase 2–signal transducers and activators of transcription signaling. The unique composition of cHL limits its analysis with high-throughput genomic assays. Therefore, the precise incidence, nature, and prognostic significance of PD-L1/PD-L2 alterations in cHL remain undefined. Methods: We used a fluorescent in situ hybridization assay to evaluate CD274/PD-L1 and PDCD1LG2/PD-L2 alterations in 108 biopsy specimens from patients with newly diagnosed cHL who were treated with the Stanford V regimen and had long-term follow-up. In each case, the frequency and magnitude of 9p24.1 alterations—polysomy, copy gain, and amplification—were determined, and the expression of PD-L1 and PD-L2 was evaluated by immunohistochemistry. We also assessed the association of 9p24.1 alterations with clinical parameters, which included stage (early stage I/II favorable risk, early stage unfavorable risk, advanced stage [AS] III/IV) and progression-free survival (PFS). Results: Ninety-seven percent of all evaluated cHLs had concordant alterations of the PD-L1 and PD-L2 loci (polysomy, 5% [five of 108]; copy gain, 56% [61 of 108]; amplification, 36% [39 of 108]). There was an association between PD-L1 protein expression and relative genetic alterations in this series. PFS was significantly shorter for patients with 9p24.1 amplification, and the incidence of 9p24.1 amplification was increased in patients with AS cHL. Conclusion: PD-L1/PD-L2 alterations are a defining feature of cHL. Amplification of 9p24.1 is more common in patients with AS disease and associated with shorter PFS in this series. Further analyses of 9p24.1 alterations in patients treated with standard cHL induction regimens or checkpoint blockade are warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378
Self-citationPD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Ansell, S. M., Lesokhin, A. M., Borrello, I., Halwani, A., Scott, E. C., Gutierrez, M., Schuster, S. J., Millenson, M. M., Cattry, D., Freeman, G. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411087 · Cited by 3,560
Self-citationGreen, M. R., Monti, S., Rodig, S. J., Juszczynski, P., Currie, T., O'Donnell, E., Chapuy, B., Takeyama, K., Neuberg, D., Golub, T. R., et al. (2010) · Blood · doi:10.1182/blood-2010-05-282780 · Cited by 1,305
Self-citationChen, B. J., Chapuy, B., Ouyang, J., Sun, H. H., Roemer, M. G. M., Xu, M. L., Yu, H., Fletcher, C. D. M., Freeman, G. J., Shipp, M. A., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0855 · Cited by 843
Self-citationThe biology of Hodgkin's lymphoma
Küppers, R. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2542 · Cited by 688
Green, M. R., Rodig, S., Juszczynski, P., Ouyang, J., Sinha, P., O'Donnell, E., Neuberg, D., & Shipp, M. A. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1942 · Cited by 685
Self-citationMHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers
Steidl, C., Shah, S. P., Woolcock, B. W., Rui, L., Kawahara, M., Farinha, P., Johnson, N. A., Zhao, Y., Telenius, A., Neriah, S. B., et al. (2011) · Nature · doi:10.1038/nature09754 · Cited by 615
Targetable genetic features of primary testicular and primary central nervous system lymphomas
Chapuy, B., Roemer, M. G. M., Stewart, C., Tan, Y., Abo, R. P., Zhang, L., Dunford, A. J., Meredith, D. M., Thorner, A. R., Jordanova, E. S., et al. (2016) · Blood · doi:10.1182/blood-2015-10-673236 · Cited by 585
Self-citationKiyasu, J., Miyoshi, H., Hirata, A., Arakawa, F., Ichikawa, A., Niino, D., Sugita, Y., Yufu, Y., Choi, I., Abe, Y., et al. (2015) · Blood · doi:10.1182/blood-2015-02-629600 · Cited by 464
Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells
Reichel, J., Chadburn, A., Rubinstein, P. G., Giulino-Roth, L., Tam, W., Liu, Y., Gaiolla, R., Eng, K., Brody, J., Inghirami, G., et al. (2015) · Blood · doi:10.1182/blood-2014-11-610436 · Cited by 337
Juszczynski, P., Ouyang, J., Monti, S., Rodig, S. J., Takeyama, K., Abramson, J., Chen, W., Kutok, J. L., Rabinovich, G. A., & Shipp, M. A. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706017104 · Cited by 327
Self-citationHorning, S. J., Hoppe, R. T., Breslin, S., Bartlett, N. L., Brown, B. W., & Rosenberg, S. A. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.3.630 · Cited by 324
Self-citationGordon, L. I., Hong, F., Fisher, R. I., Bartlett, N. L., Connors, J. M., Gascoyne, R. D., Wagner, H., Stiff, P. J., Cheson, B. D., Gospodarowicz, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.4803 · Cited by 308
Self-citationWeber, J. (2010) · Seminars in Oncology · doi:10.1053/j.seminoncol.2010.09.005 · Cited by 306
Twa, D. D. W., Chan, F. C., Ben-Neriah, S., Woolcock, B. W., Mottok, A., Tan, K. L., Slack, G. W., Gunawardana, J., Lim, R. S., McPherson, A. W., et al. (2014) · Blood · doi:10.1182/blood-2013-10-535443 · Cited by 302
Early-Stage Hodgkin's Lymphoma
Armitage, J. O. (2010) · New England Journal of Medicine · doi:10.1056/nejmra1003733 · Cited by 180
Steidl, C., Telenius, A., Shah, S. P., Farinha, P., Barclay, L., Boyle, M., Connors, J. M., Horsman, D. E., & Gascoyne, R. D. (2010) · Blood · doi:10.1182/blood-2009-12-257345 · Cited by 176
Shi, M., Roemer, M. G. M., Chapuy, B., Liao, X., Sun, H. H., Pinkus, G. S., Shipp, M. A., Freeman, G. J., & Rodig, S. J. (2014) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000297 · Cited by 158
Self-citationMahoney, K. M., Sun, H. H., Liao, X., Hua, P., Callea, M., Greenfield, E. A., Hodi, F. S., Sharpe, A. H., Signoretti, S., Rodig, S. J., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0116 · Cited by 124
Self-citationHartmann, S., Martín-Subero, J. I., Gesk, S., Husken, J., Giefing, M., Nagel, I., Riemke, J., Chott, A., Klapper, W., Parrens, M., et al. (2008) · Haematologica · doi:10.3324/haematol.12875 · Cited by 109
Ansell, S. M., Armand, P. A., Timmerman, J. M., Shipp, M. A., Bradley‐Garelik, M. B., Zhu, L., & Lesokhin, A. M. (2015) · Blood · doi:10.1182/blood.v126.23.583.583 · Cited by 70
Self-citationArmand, P. A., Shipp, M. A., Ribrag, V., et al. (2015) · Blood · doi:10.1182/blood.v126.23.584.584 · Cited by 36
Self-citation
Cited by
Alaggio, R., Amador, C., Anagnostopoulos, I., Attygalle, A. D., Araujo, I. B. D. O., Berti, E., Bhagat, G., Borges, A. M., Boyer, D., Calaminici, M., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01620-2 · Cited by 4,004
Self-citationRegulation and Function of the PD-L1 Checkpoint
Sun, C., Mezzadra, R., & Schumacher, T. N. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.014 · Cited by 2,193
The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker
Jardim, D. L., Goodman, A., de Melo Gagliato, D., & Kurzrock, R. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.10.001 · Cited by 1,192
Mechanisms Controlling PD-L1 Expression in Cancer
Cha, J.-H., Chan, L.-C., Li, C.-W., Hsu, J. L., & Hung, M.-C. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.09.030 · Cited by 1,045
Ott, P. A., Bang, Y.-J., Piha-Paul, S. A., Razak, A. R. A., Bennouna, J., Soria, J.-C., Rugo, H. S., Cohen, R. B., O’Neil, B. H., Mehnert, J. M., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.2276 · Cited by 969
Metadata
- Authors
- Roemer, M. G. M., Advani, R. H., Ligon, A. H., Natkunam, Y., Redd, R. A., Homer, H., Connelly, C. F., Sun, H. H., Daadi, S. E., Freeman, G. J., Armand, P., Chapuy, B., de Jong, D., Hoppe, R. T., Neuberg, D. S., Rodig, S. J., & Shipp, M. A.
- Venue
- Journal of Clinical Oncology
- Published
- 2016-08-10
- Volume
- 34
- Issue
- 23
- Pages
- 2690-2697
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2337659275
- Cited by
- 791
- References
- 22
- FWCI
- 80.52
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.